secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001437749-23-031065
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q3 net loss improves to $2.0M; MNPR-101 radiopharma on track for first-in-human Dec 2023
--------------------------------------------------------------------------------

- Net loss $2.0M ($0.14/share) vs $2.4M ($0.19) YoY; cash and equivalents $8.5M.
- MNPR-101 radiopharma program to enter first-in-human study possibly as early as December 2023.
- Camsirubicin Phase 1b at fifth dose cohort (650 mg/m^2); two patients showed tumor reductions of ~18% and 20%.
- CTOS data: 9 of 14 stable disease, no DLT; one patient with LVEF decrease being assessed for cardiotoxicity.
- Cash runway through November 2024; company expects to seek additional capital within 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/0001437749-23-031065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/mnpr20231030d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer